EMIS Group plc EMIS Group Investing in Annual report and accounts 2019 and accounts Annual report innovation EMIS Group plc Annual report and accounts 2019 Delivering the strategy Strategic report The UK leader in connected 1 Highlights 2 At a glance healthcare software and systems. 4 Chair’s statement 6 Chief Executive Officer’s statement 10 Business model INNOVATION 12 Stakeholder engagement 14 Markets EMIS Group is focussed on innovation for the NHS 16 Strategy and business-to-business (B2B) healthcare industry. 20 Key performance indicators 22 Alternative performance measures Innovative technology will drive improvements to 24 Principal risks and uncertainties healthcare efficiency and better patient outcomes. 30 Operational review 34 Financial review 38 Our people GROWTH 41 Sustainability policy EMIS Group delivered positive revenue growth and Governance adjusted profit growth, maintaining its nine-year track 42 Board of Directors record of increasing dividends by 10% year on year. 44 Chair’s introduction to governance 45 Corporate governance statement 51 Report of the audit committee 56 Report of the nomination committee 58 Report of the remuneration committee 61 Remuneration at a glance 63 Directors’ remuneration report 68 Directors’ report 71 Viability statement 72 Statement of Directors’ responsibilities Financial statements 73 Independent auditor’s report 78 Group statement of comprehensive income 79 Group and parent company balance sheets 80 Group and parent company statements of cash flows 81 Group and parent company statements of changes in equity 82 Notes to the financial statements 107 Five-year Group financial summary 108 Shareholder information Highlights OPERATIONAL Results in line with expectations, with growth in both revenue and adjusted operating profit maintained at similar levels to the half year along with further strategic progress: • Leadership positions maintained in key NHS markets • Improved our operational efficiency, service and responsiveness to customers • EMIS Health appointed to the NHS National Services Scotland (NSS) and the NHS GP IT Futures framework and Digital • Robust and resilient business model with 78% recurring Buying Catalogue in England revenues, net cash and market leading positions in key healthcare markets • Expanded the EMIS Enterprise business achieving outright leadership in community pharmacy • As part of the focus on future strategy, completed the internal Key performance indicators page 20 transition and organisational plans underway through the year FINANCIAL Total revenue Reported cash generated Reported EPS from operations £159.5m +7% 36.0p – £50.1m – Recurring revenue1 Adjusted EPS1 Adjusted cash generated £125.0m +4% from operations1 51.4p +14% Reported operating profit £46.3m -15% Total dividend for the year £26.8m -3% Net cash 31.2p +10% Adjusted operating profit1 £31.1m +£15.5m £39.3m +9% 1 Recurring revenue, adjusted operating profit, adjusted cash generated from operations and adjusted EPS are all alternative performance measures. See page 22 for further details and reconciliation to the relevant IFRS number. EMIS Group plc Annual report and accounts 2019 1 STRATEGIC REPORT At a glance PURPOSE Enable better care through technology innovation • Connecting care settings to improve patient experience and health outcomes • Empowering people through online access to clinically authored content and approved services • Delivering insight for clinicians to improve UK health and wellness WHY DOES THE OPPORTUNITY EXIST? WHY INVEST IN EMIS? The NHS Long Term Plan is driving the • Strong positions in specialist markets agenda for integrated care, delivered • Opportunity to strengthen position in B2B healthcare sector markets over time both organically and by selective through technology. bolt-on acquisition • Excellent financial strength and track record £4.5bn 2023–24 • High levels of earnings visibility and cash generation is committed to increasing deadline for every patient to • New technology driving future growth and efficiency primary and community be offered digitally enabled healthcare primary care Read more at emisgroupplc.com Markets page 14 EMIS Group plc 2 Annual report and accounts 2019 SEGMENTS EMIS HEALTH EMIS ENTERPRISE Primary, community Medicines Partners and Patient-facing and acute care management other services services 63% 22% 13% 2% of revenue in 2019 of revenue in 2019 of revenue in 2019 of revenue in 2019 #1 in primary care #1 in community 113 accredited #1 patient pharmacy partners services app #2 in community #2 in hospital #1 in A&E pharmacy BRANDS The clinical software Dedicated to providing The UK’s leading business, supplying specialist ICT infrastructure, independent provider of innovative and essential hardware and engineering patient-centric medical and technology to 10,000 services and non-clinical well-being information and healthcare organisations software into health and related transactional services. across every major UK social care. health sector. EMIS Group plc Annual report and accounts 2019 3 STRATEGIC REPORT Chair’s statement “We are focussed on delivering our strategy.” Mike O’Leary Chair EMIS Group plc 4 Annual report and accounts 2019 A year of good progress EMIS Group delivered higher rates of growth both to revenue and adjusted profit. Dear Shareholder Corporate governance I am pleased to report a year of good progress for EMIS Group. Corporate governance remains an important area of focus for the We have delivered higher rates of growth both to revenue and adjusted Board and underpins the sustainability of our business and the profit. We have maintained our nine-year track record of increased achievement of our strategy. The Board has taken steps to consider annual dividends. We have also completed the internal transformation and strengthen our governance to align with the new Code, in of the business and we are focussed on delivering our strategy. particular in the areas of stakeholder and workforce engagement. Further details of our approach to the Code are set out in our corporate governance statement on pages 45 to 50. Talent, culture and diversity During 2019 we continued to attract and retain key talent, selecting and developing exceptional people who are motivated by our purpose. Dividend Our teams comprise people driven to grow their areas of the business A final dividend of 15.6p per share is recommended by the Board. in the mid and long term. We are thoughtful in our approach to recruitment The dividend progression is in line with the capital allocation policy and retention and have robust succession plans in place. I would like adopted by the Group and will result in a total dividend for the year to thank all of our employees for delivering such a strong performance of 31.2p. Subject to approval by shareholders at the AGM, the final through their commitment, hard work and support of the Group. dividend will be paid on 11 May 2020 to shareholders on the register on 14 April 2020. A positive culture and employee engagement are fundamental contributors to success. I am pleased to report that an independent culture audit this year saw a very high response rate with continued Outlook strong engagement at all levels. This will be an ongoing area of focus 2019 finished strongly and, as noted above, revenue and adjusted during 2020. profit growth have both been encouraging. Innovation remains key for our future and we will continue to invest in technology Diversity in all forms brings material benefit to EMIS Group and we development. Our strategy remains closely aligned with NHS policy, seek to provide opportunities for all, regardless of background, age, which will drive growth for both the EMIS Health and EMIS Enterprise gender or race. The gender diversity of our business has been areas of the business. We are unique in the breadth of markets we enhanced with the appointment of Jen Byrne as a Non-executive serve and the strong market positions we hold. We remain well Director of the Group in May 2019 and Suzy Foster as CEO of EMIS positioned for future success. Health in April 2019. We will continue to promote diversity throughout the organisation. Mike O’Leary Board changes Chair As reported in the 2018 annual report and accounts, following 17 March 2020 completion of nine years of service, Robin Taylor retired on 8 May 2019 at the conclusion of the 2019 Annual General Meeting (AGM), following which Kevin Boyd took on the role of chair of the audit committee and Andy McKeon took on the role of Senior Independent Director. Stakeholder engagement page 12 On 22 August 2019 David Sides resigned from the Board following his appointment to a new executive role in the United States. I would like to thank both Robin and David for their contributions to EMIS Group over an extended period. We were delighted to appoint Jen Byrne to the Board on 8 May 2019 and she has taken up the role of designated Non-executive Director for engagement with our workforce. This is a new role introduced in compliance with the 2018 UK Corporate Governance Code (“the Code”), which we have chosen to apply voluntarily. We were also extremely pleased to appoint Patrick De Smedt to the “I would like to thank all of our Board on 1 January 2020 as Chair designate. Patrick will take over from me as Chair on my retirement at the conclusion of our AGM employees for delivering such on 6 May 2020. I would like to welcome Patrick and wish him every success in the Chair role. I have thoroughly enjoyed the nine years a strong performance through that I have spent at EMIS Group and would like to thank my fellow their commitment, hard work Board members and all of the Group’s employees for their support during my tenure as Chair. and support of the Group.” EMIS Group plc Annual report and accounts 2019 5 STRATEGIC REPORT Chief Executive Officer’s statement “A positive year for EMIS Group.” Andy Thorburn Chief Executive Officer EMIS Group plc 6 Annual report and accounts 2019 Considerable operational progress We achieved key customer retention goals and maintained our leadership positions in key NHS markets.